Adrienne Samani

Adrienne Samani

Auto-generated profile, based on publicly available information

Adrienne Samani

Division of Neurology, Department of Pediatrics University of Alabama at Birmingham and Children's of Alabama Birmingham Alabama USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
ARAndrea L Reid
Andrea L Reid
YWYimin Wang
Yimin Wang
ASAdrienne Samani
Adrienne Samani
RHRylie M Hightower
Rylie M Hightower
MLMichael Alonzo Lopez
Michael Alonzo Lopez
MAMatthew S Alexander
Matthew S Alexander
DOCK3 is a member of the DOCK family of guanine nucleotide exchange factors that regulate cell migration, fusion and viability. Previously, we identified a dysregulated miR-486/DOCK3 signaling cascade in dystrophin-deficient muscle, which resulted in the overexpression of DOCK3; however, little is known about the role of DOCK3 in muscle. Here, we characterize the functional role of DOCK3 in normal and dystrophic skeletal muscle. Utilizing Dock3 global knockout (Dock3 KO) mice, we found that the haploinsufficiency of Dock3 in Duchenne muscular dystrophy mice improved dystrophic muscle pathologies; however, complete loss of Dock3 worsened muscle function. Adult Dock3 KO mice have impaired muscle function and Dock3 KO myoblasts are defective for myogenic differentiation. Transcriptomic analyses of Dock3 KO muscles reveal a decrease in myogenic factors and pathways involved in muscle differentiation. These studies identify DOCK3 as a novel modulator of muscle health and may yield therapeutic targets for treating dystrophic muscle symptoms.

24 September 2023 in The FASEB Journal
Verified
Journal Article
Closed access
ASAdrienne Samani
Adrienne Samani
MKMuthukumar Karuppasamy
Muthukumar Karuppasamy
KEKatherine Grace English
Katherine Grace English
CSColin A. Siler
Colin A. Siler
YWYimin Wang
Yimin Wang
MAMatthew S Alexander
Matthew S Alexander

26 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
KEKatherine Grace English
Katherine Grace English
ARAndrea L. Reid
Andrea L. Reid
ASAdrienne Samani
Adrienne Samani
GCGerald J. F. Coulis
Gerald J. F. Coulis
SVS. Armando Villalta
S. Armando Villalta
MAMatthew S Alexander
Matthew S Alexander
Duchenne muscular dystrophy (DMD) is a progressive, X-linked childhood neuromuscular disorder that results from loss-of-function mutations in the DYSTROPHIN gene. DMD patients exhibit muscle necrosis, cardiomyopathy, respiratory failure, and loss of ambulation. One of the major driving forces of DMD disease pathology is chronic inflammation. The current DMD standard of care is corticosteroids; however, there are serious side effects with long-term use, thus identifying novel anti-inflammatory and anti-fibrotic treatments for DMD is of high priority. We investigated the next-generation SINE compound, KPT−8602 (eltanexor) as an oral therapeutic to alleviate dystrophic symptoms. We performed pre-clinical evaluation of the effects of KPT−8602 in DMD zebrafish (sapje) and mouse (D2-mdx) models. KPT−8602 improved dystrophic skeletal muscle pathologies, muscle architecture and integrity, and overall outcomes in both animal models. KPT−8602 treatment ameliorated DMD pathology in D2-mdx mice, with increased locomotor behavior and improved muscle histology. KPT−8602 altered the immunological profile of the dystrophic mice, and reduced circulating osteopontin serum levels. These findings demonstrate KPT−8602 as an effective therapeutic in DMD through by promotion of an anti-inflammatory environment and overall improvement of DMD pathological outcomes.

28 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAndrea L. Reid
Andrea L. Reid
YWYimin Wang
Yimin Wang
ASAdrienne Samani
Adrienne Samani
RHRylie M. Hightower
Rylie M. Hightower
MLMichael Alonzo Lopez
Michael Alonzo Lopez
MAMatthew S Alexander
Matthew S Alexander
DOCK3 is a member of the DOCK family of guanine nucleotide exchange factors that function to regulate cell migration, fusion, and overall viability. Previously, we identified a miR-486/Dock3 signaling cascade that was dysregulated in dystrophin-deficient muscle which resulted in the overexpression of DOCK3 , however not much else is known about the role of DOCK3 in muscle. In this work, we characterize the functional role of DOCK3 in normal and dystrophic skeletal muscle. By utilizing Dock3 global knockout ( Dock3 KO) mice, we found reducing Dock3 gene via haploinsufficiency in DMD mice improved dystrophic muscle histology, however complete loss of Dock3 worsened overall muscle function on a dystrophin-deficient background. Consistent with this, Dock3 KO mice have impaired muscle architecture and myogenic differentiation defects. Moreover, transcriptomic analyses of Dock3 knockout muscles reveal a decrease in factors known for myogenesis, suggesting a possible mechanism of action. These studies identify DOCK3 as a novel modulator of muscle fusion and muscle health and may yield additional therapeutic targets for treating dystrophic muscle symptoms.

15 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
RHRylie M. Hightower
Rylie M. Hightower
ASAdrienne Samani
Adrienne Samani
ARAndrea L. Reid
Andrea L. Reid
KEKatherine G. English
Katherine G. English
MLMichael Alonzo Lopez
Michael Alonzo Lopez
MAMatthew S Alexander
Matthew S Alexander
Duchenne muscular dystrophy (DMD) is an X-linked progressive muscle disorder resulting in muscle weakness and cardiomyopathy. MicroRNAs have been shown to play essential roles in muscle development, metabolism, and disease pathologies. We demonstrated that miR-486 expression is reduced in DMD muscles and its expression levels correlate with dystrophic disease severity. MicroRNA-486 knockout mice developed disrupted myofiber architecture, decreased myofiber size, decreased locomotor activity, increased cardiac fibrosis, and metabolic defects that were exacerbated on the dystrophic mdx 5cv background. We integrated RNA-sequencing and chimeric eCLIP-sequencing data to identify direct in vivo targets of miR-486 and associated dysregulated gene signatures in skeletal muscle. In comparison to our DMD mouse muscle transcriptomes, we identified several of these miR-486 muscle targets including known modulators of dystrophinopathy disease symptoms. Together, our studies identify miR-486 as a driver of muscle remodeling in DMD, a useful biomarker for dystrophic disease progression, and highlight chimeric eCLIP-sequencing as a useful tool to identify direct in vivo microRNA target transcripts. Abstract Figure: